Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results


enforce adequate patent and other intellectual property protection of

our product candidates, and

-- risks of collaborating with third parties to develop and commercialize


These and other risks are described in greater detail in our Annual Report on Form 10-K for the year ended December 31, 2007, and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements because of these uncertainties, and the inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. We assume no obligation to update forward-looking statements. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Table 1

Amicus Therapeutics, Inc.

(a development stage company)

Consolidated Statements of Operations


(In thousands, except share and per share amounts)

Period from

February 4,


Three Months Nine Months (inception)

Ended Ended to

September 30, September 30, September 30,

2007 2008 2007 2008 2008



revenue $ - $2,959 $ - $8,539 $9,913


revenue - 694 - 2,083 2,491

Total revenue - 3,653 - 10,622 12,404


SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  Today the Wyss Institute ... launch of its start-up company Opsonix Inc. ... Harvard,s Office of Technology Development (OTD) and ... sepsis therapy for clinical use. ... least a million people every year in the U.S. ...
(Date:10/8/2015)... TORONTO, CANADA (PRWEB) , ... October 08, 2015 ... ... it has entered into an exclusive license agreement to develop and commercialize intellectual ... expands upon the original agreement from February 2009, and affords exclusive worldwide rights ...
(Date:10/7/2015)... 7, 2015 Boston Scientific (NYSE: ... the Boston Scientific Connected Patient Challenge , an ... use of remote patient monitoring to enhance patient care.  ... can submit their ideas and collaborate on solutions through ... Cambridge, MA where they ...
(Date:10/7/2015)... 7, 2015  ChromaDex Corp. (OTCQX: CDXC), an ... that creates science-based solutions for dietary supplement, food ... products, today announced that the October 1 presentation ... is now available for on-demand viewing at ...   --> LINK: ...
Breaking Biology Technology:
... Networks Corp. has been recognized by Microsoft ... services. , ,The Madison-based IT solutions provider this month ... Midwest to achieve Microsoft's Enterprise Project Management (EPM) specialization. ... expertise in serving businesses that require the tools and ...
... Wis. Higher revenue from its clinical molecular diagnostic products ... a loss for the quarter ending March 31, 2006. , ,Third ... of $4.4 million, or ($0.11) a diluted share, for the first ... net loss of $4.4 million, or ($0.11) a diluted share, for ...
... Wis. Fiserv, which provides software and services ... revenues in 2006 were up 13 percent to $1.1 ... from the $140 million the company made in the ... , ,Fiserve's activities in the first quarter included repurchasing ...
Cached Biology Technology:
(Date:9/28/2015)... , September 28, 2015 ... Component (Hardware & Software), Product (Scanner & Others), Application ... & Defense, & Others) & Geography Global - Forecast ... expected to reach USD 3627.90 Million by 2020, at ... Browse 65 market data T ables ...
(Date:9/24/2015)... , Sept. 24, 2015  EyeLock LLC, a ... showcasing its award winning and latest technology in Booth ... Anaheim, California . EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:9/10/2015)... LONDON , Sept. 10, 2015 ... This New Study Reveals Selling Opportunities and Revenue ... What,s the future of biologics, especially new drug ... You will stay ahead with exclusive market data ... can explore trends, developments, results, opportunities and sales ...
Breaking Biology News(10 mins):
... is often compared to a book. However, it is not so ... rather like a cookbook. The cell reads only those recipes which ... genes; ,reading, in the book of the cell means creating RNA ... The cell uses highly complex, sophisticated regulatory mechanisms to ...
... have created mice that can "smell" light, providing a potent ... basis of olfaction. The work, described this week in ... future study of smell and of complex perception systems that ... "It makes intuitive sense to use odors to study ...
... thousand federal, state and local leaders and physical security ... Regional Airport next May 17-19 to observe demonstrations of ... to personnel, equipment and facilities - in combat zones ... and abroad. Military and civilian representatives of ...
Cached Biology News:
... for all types of yeast two-hybrid studies, including complex ... Choice of two bait vectors for maximum ... Triple reporter strain NMY51 ... Complete set of controls: pLexA-p53, pLexA-lamin ...
... Quickly, effectively seals labware. Waterproof, ... protects anhydrous materials. Can be folded ... without rupturing. Stretched lengthwise at 21C ... Yet when tension is removed, film ...
Human Serum FDA Licensed US Donor Centers Sterile / Non-sterile: Sterile Filtered to 0.2 micron Information: Extensive Viral Testing ...
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
Biology Products: